{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T08:54:30Z","timestamp":1754556870350},"reference-count":15,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2004,11,1]],"date-time":"2004-11-01T00:00:00Z","timestamp":1099267200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gastroenterology"],"published-print":{"date-parts":[[2004,11]]},"DOI":"10.1053\/j.gastro.2004.08.016","type":"journal-article","created":{"date-parts":[[2005,7,29]],"date-time":"2005-07-29T14:31:14Z","timestamp":1122647474000},"page":"1322-1328","source":"Crossref","is-referenced-by-count":25,"title":["Risks of clinically significant upper gastrointestinal events with etodolac and naproxen: A historical cohort analysis"],"prefix":"10.1053","volume":"127","author":[{"given":"Rick A.","family":"Weideman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin C.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salahuddin","family":"Kazi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anh","family":"Cung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin W.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herbert J.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr","given":"George A.","family":"Sarosi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bertis B.","family":"Little","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byron","family":"Cryer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.gastro.2004.08.016_bib1","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1056\/NEJM199906173402407","article-title":"Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs","volume":"340","author":"Wolfe","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2004.08.016_bib2","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/jama.284.10.1247","article-title":"Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis","volume":"284","author":"Silverstein","year":"2000","journal-title":"JAMA"},{"key":"10.1053\/j.gastro.2004.08.016_bib3","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJM200011233432103","article-title":"Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis","volume":"343","author":"Bombardier","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1053\/j.gastro.2004.08.016_bib4","doi-asserted-by":"crossref","first-page":"7563","DOI":"10.1073\/pnas.96.13.7563","article-title":"Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity","volume":"96","author":"Warner","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.gastro.2004.08.016_bib5","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0016-5107(95)70045-5","article-title":"A randomized, double-blind comparison of placebo, etodolac, and naproxen on gastrointestinal injury and prostaglandin production","volume":"42","author":"Laine","year":"1995","journal-title":"Gastrointest Endosc"},{"key":"10.1053\/j.gastro.2004.08.016_bib6","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1001\/jama.282.20.1929","article-title":"Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs","volume":"282","author":"Langman","year":"1999","journal-title":"JAMA"},{"key":"10.1053\/j.gastro.2004.08.016_bib7","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1111\/j.1572-0241.2000.02194.x","article-title":"Reduced risk of upper gastrointestinal ulcers with celecoxib, a COX-2 inhibitor","volume":"95","author":"Goldstein","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2004.08.016_bib8","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1053\/gast.2001.21907","article-title":"Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient","volume":"120","author":"Laine","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2004.08.016_bib9","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/S0140-6736(02)07370-1","article-title":"Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease","volume":"359","author":"Ray","year":"2002","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2004.08.016_bib10","doi-asserted-by":"crossref","first-page":"787","DOI":"10.7326\/0003-4819-115-10-787","article-title":"Risk for serious gastrointestinal complications related to the use of nonsteroidal anti-inflammatory drugs. A meta-analysis","volume":"115","author":"Gabriel","year":"1991","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.gastro.2004.08.016_bib11","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/S0140-6736(02)11131-7","article-title":"COX-2 selective non-steroidal anti-inflammatory drugs and risks of serious coronary heart disease","volume":"360","author":"Ray","year":"2002","journal-title":"Lancet"},{"key":"10.1053\/j.gastro.2004.08.016_bib12","first-page":"38","article-title":"Double-blind comparison of etodolac and naproxen in the treatment of rheumatoid arthritis","volume":"13","author":"de Queiros","year":"1991","journal-title":"Clin Ther"},{"key":"10.1053\/j.gastro.2004.08.016_bib13","first-page":"648","article-title":"Single-blind, randomized, parallel-group study of etodolac and naproxen in patients with osteoarthritis","volume":"46","author":"Fioravanti","year":"1989","journal-title":"Curr Ther Res"},{"key":"10.1053\/j.gastro.2004.08.016_bib14","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1185\/03007999109111513","article-title":"Effectiveness of etodolac (Lodine) compared with naproxen in patients with acute gout","volume":"12","author":"Maccagno","year":"1991","journal-title":"Curr Med Res Opin"},{"key":"10.1053\/j.gastro.2004.08.016_bib15","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1053\/gast.2002.36013","article-title":"Stratifying the risk of NSAID-related upper gastrointestinal clinical events","volume":"123","author":"Laine","year":"2002","journal-title":"Gastroenterology"}],"container-title":["Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508504014064?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508504014064?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,23]],"date-time":"2019-01-23T22:57:54Z","timestamp":1548284274000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0016508504014064"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,11]]},"references-count":15,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2004,11]]}},"alternative-id":["S0016508504014064"],"URL":"https:\/\/doi.org\/10.1053\/j.gastro.2004.08.016","relation":{},"ISSN":["0016-5085"],"issn-type":[{"value":"0016-5085","type":"print"}],"subject":[],"published":{"date-parts":[[2004,11]]}}}